Bridge Biotherapeutics, Inc. (KOSDAQ: 288330)

Bridge Biotherapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	16,934	14,183	7,942	8,200	20,943	64,087
Short-Term Investments	8,690	6,000	39,500	29,000	37,000	-0
Trading Asset Securities	-	-	3,852	5,928	-	5,069
Cash & Short-Term Investments	25,624	20,183	51,295	43,128	57,943	69,157
Cash Growth	-6.88%	-60.65%	18.94%	-25.57%	-16.21%	772.17%
Accounts Receivable	1.08	-0	-	-	572.25	-
Other Receivables	236.32	647.21	904.91	365.75	1,171	3,084
Receivables	237.4	647.21	904.91	365.75	1,743	3,084
Inventory	-	-	-	-	-	1,933
Prepaid Expenses	152.96	217.98	274.3	305.32	313.24	88.6
Other Current Assets	970.43	683.25	2,483	627.33	304.74	4,448
Total Current Assets	26,985	21,731	54,957	44,426	60,304	78,710
Property, Plant & Equipment	3,279	4,287	3,784	664.25	829.58	645.18
Long-Term Investments	740.73	890.53	470.01	94.06	0	0
Goodwill	2,888	3,899	-	-	-	-
Other Intangible Assets	2,870	226.84	131.89	179.22	223.78	271.91
Long-Term Deferred Charges	85.24	85.24	-	-	-	-
Other Long-Term Assets	832.18	1,564	2,112	1,293	2,153	109.63
Total Assets	37,680	32,683	61,455	46,657	63,510	79,737
Accrued Expenses	166.64	330.51	142.66	119.58	105.07	247.23
Current Portion of Leases	1,103	1,043	993.06	172.93	168.14	152.05
Current Unearned Revenue	-	-	-	1,076	-	3,773
Other Current Liabilities	4,648	9,002	6,359	2,188	782.26	535.5
Total Current Liabilities	5,918	10,375	7,494	3,556	1,055	4,708
Long-Term Leases	1,701	2,504	2,016	53.63	226.56	10.96
Long-Term Unearned Revenue	-	-	-	-	3,000	-
Other Long-Term Liabilities	85.58	83.22	80.17	0	-0	0
Total Liabilities	8,238	12,963	9,590	3,610	4,282	4,719
Common Stock	23,157	11,334	9,948	9,854	9,591	3,113
Additional Paid-In Capital	135,204	122,612	115,998	71,820	65,537	120,495
Retained Earnings	-145,340	-129,718	-87,397	-45,697	-19,419	-51,363
Comprehensive Income & Other	13,578	13,193	10,945	7,071	3,519	2,773
Total Common Equity	26,589	17,421	49,494	43,047	59,228	75,018
Minority Interest	1,198	419.15	-	-	-	-
Shareholders' Equity	29,442	19,720	51,865	43,047	59,228	75,018
Total Liabilities & Equity	37,680	32,683	61,455	46,657	63,510	79,737
Total Debt	2,804	3,547	3,009	226.56	394.69	163.02
Net Cash (Debt)	22,820	16,636	48,286	42,901	57,548	68,994
Net Cash Growth	-9.51%	-65.55%	12.55%	-25.45%	-16.59%	-
Net Cash Per Share	737.08	674.63	2028.30	1830.30	2517.32	5931.23
Filing Date Shares Outstanding	46.31	27.2	23.88	23.65	23.02	22.41
Total Common Shares Outstanding	46.31	27.2	23.88	23.65	23.02	22.41
Working Capital	21,067	11,356	47,462	40,870	59,249	74,002
Book Value Per Share	574.11	640.45	2073.00	1820.27	2573.19	3347.50
Tangible Book Value	20,831	13,295	49,363	42,868	59,004	74,746
Tangible Book Value Per Share	449.77	488.76	2067.48	1812.69	2563.46	3335.37
Machinery	1,132	1,173	929.29	724.31	558.1	503.19
Construction In Progress	-	-	234.4	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.